Form 4: Day One CEO Granted 592,000 Equity Awards

Day One Biopharmaceuticals CEO Jeremy Bender was granted 592,000 equity awards, including stock options and restricted stock units, effective January 30, 2026.

Summary

• Day One Biopharmaceuticals, Inc. (DAWN) CEO and Director Jeremy Bender was granted a total of 592,000 derivative securities.
• The awards consist of 355,000 stock options and 237,000 Restricted Stock Units (RSUs).
• The stock options have an exercise price of $11.16 per share.
• Stock options vest as to 1/48th of the total shares monthly, commencing February 28, 2026, subject to continued service.
• The stock options expire on January 29, 2036.
• RSUs represent a contingent right to receive one share of the Issuer's Common Stock upon settlement.
• RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15, and November 15, subject to continued service.
• The transaction date for both grants is January 30, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies strong alignment between the CEO's incentives and long-term shareholder value, typical for executive compensation in growth-oriented biotech firms.

Positives

• The significant equity grant aligns the CEO's long-term financial interests directly with the performance and growth of Day One Biopharmaceuticals, Inc.
• The multi-year vesting schedules for both stock options and RSUs incentivize executive retention and sustained strategic focus, which can contribute to long-term shareholder value.

Risks

• Vesting of both the stock options and Restricted Stock Units is contingent upon Jeremy Bender's continued provision of service to Day One Biopharmaceuticals, Inc. on each vesting date.

Future Outlook

The equity awards are structured with long-term vesting schedules, indicating an expectation of continued service and performance from the CEO over several years, aligning executive incentives with the company's future growth trajectory.

Industry Context

StockSavvy.ai notes that significant equity grants to a CEO are a common practice in the biotechnology industry to incentivize long-term leadership and align executive compensation with shareholder value creation, especially for companies in development stages like Day One Biopharmaceuticals.

Comparison to Industry Standards

• The grant of 592,000 equity awards to a CEO in the biotech sector is substantial and comparable to compensation packages seen in similar-sized biopharmaceutical companies, where equity forms a significant portion of executive pay to drive innovation and clinical success.
• Vesting schedules (4 years for options, 4 years for RSUs) are standard for executive equity compensation in the U.S. market, aiming for long-term retention and performance alignment.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of the CEO's interests with the company's long-term performance and value creation.
• Employees: No direct impact mentioned, but a stable and incentivized leadership team can positively influence overall company direction and employee morale.

Next Steps

• Jeremy Bender's continued service to Day One Biopharmaceuticals, Inc. is required for the vesting of these equity awards.
• Future SEC Form 4 filings will report any subsequent transactions by Jeremy Bender related to his holdings in Day One Biopharmaceuticals, Inc.

Key Dates

Recommendation

This Form 4 reports a standard equity grant to the CEO, aligning his interests with long-term shareholder value. While positive for governance and retention, it does not provide new operational or financial performance data to warrant a change in investment thesis, thus a 'hold' recommendation is appropriate for existing investors.

Keywords

Day One Biopharmaceuticals, DAWN, Jeremy Bender, CEO, Stock Option, Restricted Stock Units, Equity Grant, Insider Transaction, Executive Compensation, Form 4